Marga Oortgiesen Sign in to save

OpenAlex profile details not fetched

–

Citations

–

h-index

–

i10-index

Patent citations

–

Works (all)

Aachen papers

Departments & institutes in Aachen

No department could be parsed from this author's affiliation strings.

Affiliations exactly as printed on papers (10)

4× UCB Pharma, N/A, Raleigh, United States of America
2× UCB Pharma, Raleigh, North Carolina, USA
2× Department of rheumatology, UCB Pharma, Raleigh, NC, États-Unis
1× 10UCB Pharma, Raleigh, NC, USA
1× UCB Pharma Raleigh North Carolina
1× UCB Pharma, Raleigh, North Carolina
1× UCB Pharma, Raleigh, United States of America
1× UCB Pharma, N/A, Morrisville, United States of America
1× Medical, UCB Pharma, Raleigh, NC, États-Unis
1× Medical department, UCB Pharma, Raleigh, États-Unis

Papers 14 stored

All · Aachen affiliation only

AB1000 ACHIEVEMENT OF INCREASINGLY STRINGENT CLINICAL RESPONSE CRITERIA AND LOWER LEVELS OF DISEASE ACTIVITY WAS ASSOCIATED WITH GREATER IMPROVEMENTS IN PHYSICAL FUNCTION AND HRQOL IN PATIENTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS: 52-WEEK RESULTS FROM TWO PHASE 3 STUDIES ON BIMEKIZUMAB
2023 Annals of the Rheumatic Diseases article Medicine Spondyloarthritis Studies and Treatments Open access

2

citations
POS1103 BIMEKIZUMAB MAINTAINED IMPROVEMENTS IN EFFICACY ENDPOINTS AND HAD A CONSISTENT SAFETY PROFILE THROUGH 52 WEEKS IN PATIENTS WITH NON-RADIOGRAPHIC AND RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: RESULTS FROM TWO PARALLEL PHASE 3 STUDIES
2023 Annals of the Rheumatic Diseases conference-abstract Medicine Spondyloarthritis Studies and Treatments Open access

1

citations
Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials
2023 Annals of the Rheumatic Diseases article Medicine Spondyloarthritis Studies and Treatments Open access

120

citations
PCR196 Association of Clinical Response Criteria and Disease Activity Levels With Physical Function and HRQoL in Patients With Active Axial Spondyloarthritis: 16-Week Results From Two Phase 3 Randomised, Placebo-Controlled Studies
2022 Value in Health conference-abstract Medicine Spondyloarthritis Studies and Treatments Open access

0

citations
Amélioration des signes et symptômes chez des patients atteints de spondyloarthrite axiale radiographique traités par bimékizumab : résultats à 24 semaines d’une étude de phase III, multicentrique, randomisée et contrôlée par placebo
2022 Revue du Rhumatisme article Medicine Spondyloarthritis Studies and Treatments

0

citations
Amélioration des signes et symptômes chez les patients atteints de spondyloathrite axiale non radiographique traités par le bimékizumab : résultats à 24 semaines d’une étude de phase III
2022 Revue du Rhumatisme article Medicine Spondyloarthritis Studies and Treatments

0

citations
Safety and Efficacy of Bimekizumab in Patients With Active Ankylosing Spondylitis: Three‐Year Results From a Phase IIb Randomized Controlled Trial and Its Open‐Label Extension Study
2022 Arthritis & Rheumatology article Medicine Spondyloarthritis Studies and Treatments Open access

31

citations
OP0019 BIMEKIZUMAB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: 24-WEEK EFFICACY & SAFETY FROM BE MOBILE 2, A PHASE 3, MULTICENTRE, RANDOMISED, PLACEBO-CONTROLLED STUDY
2022 Annals of the Rheumatic Diseases conference-abstract Medicine Spondyloarthritis Studies and Treatments Open access

5

citations
POS0939 BIMEKIZUMAB IN PATIENTS WITH ACTIVE NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: 24-WEEK EFFICACY & SAFETY FROM BE MOBILE 1, A PHASE 3, MULTICENTRE, RANDOMISED, PLACEBO‑CONTROLLED STUDY
2022 Annals of the Rheumatic Diseases conference-abstract Medicine Spondyloarthritis Studies and Treatments Open access

5

citations
Tolérance et efficacité à long terme du bimékizumab chez les patients atteints de spondylarthrite ankylosante : résultats à 3 ans d’une étude de phase IIb
2021 Revue du Rhumatisme article Medicine Spondyloarthritis Studies and Treatments

0

citations
POS0226 BIMEKIZUMAB LONG-TERM SAFETY AND EFFICACY IN PATIENTS WITH ANKYLOSING SPONDYLITIS: 3-YEAR RESULTS FROM A PHASE 2B STUDY
2021 Annals of the Rheumatic Diseases conference-abstract Medicine Spondyloarthritis Studies and Treatments Open access

3

citations
Efficacité et sécurité d’emploi du bimekizumab dans la spondylarthrite ankylosante : résultats rapportés par les patients à 48 semaines dans une étude de phase IIb de détermination de la dose, randomisée, en double aveugle, contrôlée versus placebo
2020 Revue du Rhumatisme article Medicine Spondyloarthritis Studies and Treatments

0

citations
OP0105 EFFICACY AND SAFETY OF BIMEKIZUMAB IN ANKYLOSING SPONDYLITIS: 48-WEEK PATIENT-REPORTED OUTCOMES FROM A PHASE 2B, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY
2020 Annals of the Rheumatic Diseases conference-abstract Medicine Spondyloarthritis Studies and Treatments Open access

1

citations
Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study
2020 Annals of the Rheumatic Diseases article Medicine Spondyloarthritis Studies and Treatments Open access cited by 1 patent

134

citations

14 results

Marga Oortgiesen ▲ Sign in to save

Departments & institutes in Aachen

Papers 14 stored

Marga Oortgiesen Sign in to save